Is Tandem Diabetes Care Stock a Buy?

One promising area for biotech investors looking for growth is the diabetes market. More than 425 million adults around the world have been diagnosed with the condition, a figure that will only continue to grow over the coming years.

Because diabetes has a relatively low mortality rate and an increasing patient population, many biotech stocks that focus on this market have quickly become compelling investments. One of these is Tandem Diabetes Care (NASDAQ: TNDM), a leading manufacturer of insulin pumps used by patients with type 1 diabetes to manage their blood sugar levels. Shares of Tandem have almost doubled since the start of the year as sales continue to skyrocket.

Let's take a look at some reasons Wall Street considers Tandem Diabetes a buy and whether these reasons are justified.

Continue reading

Source Fool.com